¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antigen reactive cell"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ¹«¸®Ç׿ø, ±ºÇ׿ø
  • group-specific antigen
    ¹«¸®Æ¯ÀÌÇ׿ø, ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen
    BÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    BÇü°£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • heterophil antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • hidden antigen
    ¼ûÀºÇ׿ø
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕ¼ºÇ׿ø
  • homologous antigen
    µ¿Á¾Ç׿ø
  • human histocompatibility antigen
    »ç¶÷Á¶Á÷ÀûÇÕ¼ºÇ׿ø
  • human leukocyte antigen
    »ç¶÷¹éÇ÷±¸Ç׿ø
  • human leukocyte antigen complex
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕü
  • human leukocyte antigen complex gene
    »ç¶÷¹éÇ÷±¸Ç׿øº¹ÇÕüÀ¯ÀüÀÚ
  • incomplete antigen
    ºÒ¿ÏÀüÇ׿ø
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • spindle cell
    ¹æÃß¼¼Æ÷
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • squamous cell in situ carcinoma
    ÆíÆò¼¼Æ÷»óÇdz»¾ÏÁ¾, ÆíÆò¼¼Æ÷¾ÏÁ¾
  • stellate cell
    º°¼¼Æ÷
  • stem cell
    Áٱ⼼Æ÷
  • supporting cell
    ¹öÆÀ¼¼Æ÷
  • sustentacular cell
    (¢¡supporting cell) ¹öÆÀ¼¼Æ÷
  • target cell
    Ç¥Àû¼¼Æ÷
  • transitional cell
    ÀÌÇ༼Æ÷
  • transitional cell carcinoma
    ÀÌÇ༼Æ÷¾ÏÁ¾
  • cell line
    ¼¼Æ÷ÁÖ
  • giant cell pneumonia
    °Å´ë¼¼Æ÷Æó·Å
  • giant cell tumor
    °Å´ë¼¼Æ÷Á¾
  • granular cell tumor
    °ú¸³¼¼Æ÷Á¾¾ç
  • granulosa cell tumor
    °ú¸³Ãþ¼¼Æ÷Á¾¾ç
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • functional antigen
    ±â´ÉÇ׿ø
  • granulocyte-erythrocyte antigen
    °ú¸³±¸ÀûÇ÷±¸Ç׿ø
  • granulocyte-monocyte antigen
    °ú¸³±¸´ÜÇÙ±¸Ç׿ø
  • granulocyte-specific antigen
    °ú¸³±¸Æ¯ÀÌÇ׿ø
  • group antigen
    ±ºÇ׿ø
  • group-specific antigen
    ±ºÆ¯ÀÌÇ׿ø
  • hepatitis B core antigen
    ºñÇü°£¿°ÇÙ½ÉÇ׿ø
  • hepatitis B surface antigen
    ºñÇü°£¿°Ç¥¸éÇ׿ø
  • heterogenetic antigen
    (¢¡heterophil antigen) ÀÌÁ¾Ä£È­Ç׿ø
  • heterophil antigen
    ÀÌÁ¾Ä£È­Ç׿ø
  • hidden antigen
    ¼ûÀºÇ׿ø
  • histocompatibility antigen
    Á¶Á÷ÀûÇÕÇ׿ø
  • homologous antigen
    µ¿Á¾Ç׿ø
  • human histocompatibility antigen
    »ç¶÷Á¶Á÷ÀûÇÕÇ׿ø
  • human leukocyte antigen
    »ç¶÷¹éÇ÷±¸Ç׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • HBc antigen
    BÇü °£¿°¹ÙÀÌ·¯½º ÇÙ½ÉÇ׿ø
  • HBe Ag => hepatitis B e antigen
    B Çü °£¿° e Ç׿ø
  • HBe antigen
    BÇü °£¿°¹ÙÀÌ·¯½º eÇ׿ø
  • HBs antigen
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • HBsAg => hepatitis B surface antigen
    B Çü °£¿° s Ç׿ø
  • HDAg => hepatitis D antigen
    D Çü °£¿°Ç׿ø
  • HLA => human leukocyte antigen
    ÀÎüÁ¶Á÷ÀûÇÕÇ׿ø<ÀÎü¹éÇ÷±¸Ç׿ø>
  • HLA antigen
    HLAÇ׿ø.
  • HLA= human leukocyte antigen ; hist ocompatibility antigens ; tran splan tation antigens
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, ÀιéÇ÷±¸Ç׿ø.
  • HLA= human leukocyte antigen ; histocompatibility antigens ; transplantation anti
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, »ç¶÷¹éÇ÷±¸Ç׿ø.
  • Hepatitis B core antigen(HBc Ag)
    BÇü °£¿°ÇÙ½ÉÇ׿ø
  • I antigen
    I Ç׿ø
  • I region-associated antigen
    Ir¿¬°üÇ׿ø
  • Ia antigen
    IaÇ׿ø
  • Jk antigen/antibody
    JkÇ׿ø/Ç×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • accessible antigen
    Á¢±Ù°¡´ÉÇ׿ø, ±ÙÁ¢Ç׿ø(ÐÎïÈù÷ê«).
  • analysis, antigen
    Ç׿øºÐ¼®
  • anti-extractable nuclear antigen
    Ç×-ÃßÃ⼺ ÇÙÇ׿ø
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø(ù÷ê«)
  • antigen
    Ç׿ø
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen antibody interaction
    Ç׿øÇ×ü»óÈ£¹ÝÀÀ.
  • antigen binding capacity
    Ç׿ø°áÇÕ´É(¡­Ì¿ùêÒö).
  • antigen binding fragment
    Ç׿ø°áÇÕºÎÀ§
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen capture assay
    Ç׿øÆ÷È¹ÃøÁ¤
  • antigen combining site
    Ç׿ø°áÇպΠ(¡­Ì¿ùêÝ»).
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • Fusiform endothelial cell
    ¹æÃß³»ÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¹æÃß»ó³»ÇǼ¼Æ÷
  • Sustentacular cell
    ¹öÆÀ¼¼Æ÷
    [¿¾ ¿ë¾î] ÁöÁÖ¼¼Æ÷
  • Parietal cell
    º®¼¼Æ÷
    [¿¾ ¿ë¾î] º®¼¼Æ÷
  • Stellate myoepithelial cell
    º°±ÙÀ°»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó±Ù»óÇǼ¼Æ÷
  • Stellate cell
    º°¼¼Æ÷
    [¿¾ ¿ë¾î] ¼º»ó¼¼Æ÷
  • Cell of parathyroid gland
    ºÎ°©»ó»ù¼¼Æ÷
    [¿¾ ¿ë¾î] ºÎ°©»ó¼±¼¼Æ÷
  • Secretory synovial cell
    ºÐºñÀ±È°¼¼Æ÷
    [¿¾ ¿ë¾î] Ȱ¸·ºÐºñ¼¼Æ÷
  • Mast cell
    ºñ¸¸¼¼Æ÷
    [¿¾ ¿ë¾î] ºñ¸¸¼¼Æ÷
  • Intercalated epithelial cell
    »çÀÌ»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] Áß°£Ãþ»óÇǼ¼Æ÷
  • Interstitial cell
    »çÀÌÁú¼¼Æ÷
    [¿¾ ¿ë¾î] °£Áú¼¼Æ÷
  • Epithelial reticular cell
    »óÇǼ¼¸Á¼¼Æ÷
    [¿¾ ¿ë¾î] »óÇǼº¼¼¸Á¼¼Æ÷
  • Pigment epithelial cell
    »ö¼Ò»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] »ö¼Ò»óÇǼ¼Æ÷
  • Glandular cell
    »ù¼¼Æ÷
    [¿¾ ¿ë¾î] ¼±¼¼Æ÷
  • Ciliated ependymal cell
    ¼¶¸ð³ú½Ç¸·¼¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð»óÀǼ¼Æ÷
  • Ciliated epithelial cell
    ¼¶¸ð»óÇǼ¼Æ÷
    [¿¾ ¿ë¾î] ¼¶¸ð»óÇǼ¼Æ÷
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • amplifier T cell
    Áõ½Ä T ¼¼Æ÷(ñòãÖ T á¬øà)
  • APUD cell
    APUD ¼¼Æ÷(á¬øà)
  • argentaffin cell
    ¾Æ¸£Á¨Å¸ÇÉ ¼¼Æ÷(á¬øà)
  • autosynthetic cell
    ÀÚ°¡ÇÕ¼º¼¼Æ÷ (í»Ê«ùêà÷á¬øà)
  • barrier layer cell
    À庮Ãþ(î¡Ûúöµ) ¼¼Æ÷(á¬øà)
  • B cell
    B ¼¼Æ÷(á¬øà)
  • cell adhesion
    ¼¼Æ÷ºÎÂø(á¬øàÜõó·)
  • cell adhesion molecule
    ¼¼Æ÷ºÎÂøºÐÀÚ(á¬øàÜõó·ÝÂí­)
  • cell affinity
    ¼¼Æ÷ģȭ(á¬øàöÑûú)
  • cell blotting
    ¼¼Æ÷(á¬øà) ºí·ÔÆÃ
  • cell cloning
    ¼¼Æ÷(á¬øà) Ŭ·Î´×
  • cell coat
    ¼¼Æ÷(á¬øà)²®Áú
  • cell cycle
    ¼¼Æ÷ÁÖ±â(á¬øàñÎÑ¢)
  • cell differentiation
    ¼¼Æ÷ºÐÈ­(á¬øàÝÂûù)
  • cell envelope
    ¼¼Æ÷(á¬øà)½Î°³
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 8 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • small cleaved cell
    ¼ÒºÐÇÒ¼¼Æ÷
  • spindle cell
    ¹æÃ߻󼼯÷
  • squamous cell carcinoma
    ÆíÆò¼¼Æ÷¾ÏÁ¾
  • stem cell
    °£¼¼Æ÷
  • stromal cell
    °£Áú¼¼Æ÷
  • T cell ¡ìthymus derived lymphocyte¡í
    T¼¼Æ÷ ¡ì Èä¼±À¯·¡ ¸²ÇÁ±¸¡í
  • tumor cell
    Á¾¾ç¼¼Æ÷
  • white blood cell
    ¹éÇ÷±¸
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
IRIg insulin-reactive immunoglobulin
PERRLA pupils equal, round, and reactive to light and accommodation
PORH postoperative reactive hyperemia
PRA panel-reactive antibody; phosphoribosylamine; physician recognition award; plasma renin activity; pr...
PUM peanut-reactive urinary mucin
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
RO Reactive oxygen
ROI Reactive oxygen intermediate
ROM Reactive oxygen metabolite
RT Reactive thrombocytosis
sCRP Serum C-reactive protein
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • Abbe-Zeiss counting cell
    ¾Ðº£-ÀÚÀ̽º Ç÷±¸ °è»ê
  • abnormality of cell interaction
    ¼¼Æ÷ »óÈ£ÀÛ¿ë ÀÌ»ó
    ¼¼Æ÷ »çÀÌ¿¡ ÀϾ´Â ÀÛ¿ëÀÌ ºñÁ¤»óÀûÀÎ °Í.
  • absolute cell increase
    Àý´ë ¼¼Æ÷ ¼ö Áõ°¡
  • absorptive cell
    Èí¼ö ¼¼Æ÷
  • accessory cell
    ºÎ¼¼Æ÷
    °ñÀú¼± Áß¿¡¼­ ÁÖ¼¼Æ÷, ¹æ¼¼Æ÷¿¡ ¼¯¿©¼­ Á¸ÀçÇÑ´Ù. ÀÔ¹æÇüÀ̸ç Á¡¾×¼ºÀÇ ¹°ÁúÀ» °£Á÷ÇÑ´Ù. ÇÙÀº ¼¼Æ÷Àú¿¡ Ä¡¿ìÃÄ ÀÖ¾î ÆíÆò¿¡ °¡±õ´Ù.
  • acinic cell carcinoma
    ¼±¹æ ¼¼Æ÷ ¾ÏÁ¾
    1. ¼±¹æ ¼¼Æ÷, ±Ù»óÇǼ¼Æ÷°¡ Áõ½ÄÇÏ¿© Çü¼ºµÇ°í ³·Àº ¾Ç¼ºµµ¸¦ º¸ÀδÙ. 2. Ÿ¾×¼± ¾à¼º Á¾¾ç Áß 5¹øÂ°ÀÇ ¹ß»ý ºñÀ²À» °®´Â Á¾¾çÀ¸·Î 90%¿¡¼­ ÀÌÇϼ±¿¡¼­ ¹ß»ýÇÏ¸ç ¾ÇÇϼ±°ú ¼ÒŸ¾×¼±¿¡¼­µµ µå¹°°Ô ¹ß»ýÇÑ´Ù. ¿©¼º¿¡¼­ ´Ù¼Ò È£¹ßÇϰí, ¾î´À ¿¬·É¿¡¼­³ª ¹ß»ýÇϳª ÁÖ·Î 30-70´ë¿¡ °ñ°í·ç ¹ß»ýÇÑ´Ù. ¿¹Àü¿¡´Â ¾ç¼ºÀ¸·Î »ý°¢ÇÏ¿© ¼±¹æ¼¼Æ÷Á¾À̶ó ºÎ¸¥ ÀûÀÌ ÀÖÀ¸³ª ºÐ¸íÇÑ ¾Ç¼ºÀ¸·Î ¼±¾ÏÁ¾À¸·Î ºÎ¸¥´Ù. Á¾¾ç ¼¼Æ÷´Â Àå¾×¼º ¼±¹æ¼¼Æ÷¿Í À¯»çÇÏÁö¸¸ ¿©·¯ °¡Áö ´Ù¸¥ ¼¼Æ÷µéÀÌ ³ªÅ¸³ª¸ç, °³Á¦°ü ¿¹ºñ¼¼Æ÷¿¡¼­ ±â¿øÇÑ´Ù°í º»´Ù.
  • adamantinoid basal cell carcinoma
    ¹ý¶û Á¾¾ç ±âÀú¼¼Æ÷¾Ï
  • adenoid basal cell carcinoma
    ¼±»ó ±âÀú¼¼Æ÷¾Ï
  • adenosquamous cell carcinoma
    ¼± ÆíÆò»óÇÇ ¼¼Æ÷¾Ï
    ¼± ¾Ï°ú ÆíÆò¼¼Æ÷ ¾ÏÀÌ È¥ÀçµÇ¾î ÀÖ´Â °Í. ÀÚ±Ã°æ ³»¸· »óÇÇÀÇ ±âÀú Ãþ¿¡ ÀÖ´Â ¿¹ºñ ¼¼Æ÷¿¡¼­ ¹ß»ý. ÀÌ´Â °°Àº º´±âÀÇ ÆíÆò¼¼Æ÷ ¾Ï°ú ºñ±³ÇÏ¿© ¿¹Èİ¡ ´õ ³ª»Ú´Ù.
  • adipose cell
    Áö¹æ ¼¼Æ÷
    Áö¹æÀ» °¡Áø ¼¼Æ÷·Î¼­ ¼¼Æ÷´Â ±¸ÇüÀ» ÀÌ·ç°í, ÇÙÀº ÇÑ ÂÊÀ¸·Î Ä¡¿ìÃÄ ÀÖ´Ù.
  • adrenal medullary chromaffin cell
    ºÎ½Å ¼öÁú Å©·Ò ģȭ ¼¼Æ÷
  • adult T cell leukemia
    ¼ºÀÎ T¼¼Æ÷ ¹éÇ÷º´
    ¹ßÁõ ¿¬·ÉÀº Æò±Õ 51¼¼, ÀϺ» Kyushu, Shikoku, Kii ¹Ýµµ Áö¹æ¿¡¼­ ´Ù¹ßÇϰí ÇǺΠħÀ± ¹× °£Àå, ºñÀå, ¸²ÇÁÀý Á¾´ë¸¦ ÈçÈ÷ º¼ ¼ö Àִµ¥ ºóÇ÷Àº ¾ø´ø°¡, À־ °æµµ, °ñ¼ö¿¡ÀÇ Ä§À±Àº º¸Åë ÇöÀúÇÏÁö ¾Ê´Ù. 50% »ýÁ¸Àº 4.4°³¿ù·Î ª´Ù. ¹éÇ÷º´ ¼¼Æ÷ÀÇ Æ¯Â¡Àº ÇÙÀÌ ÀÌÇüÀÌ¸ç ºÐ¿±»ó, È­ÆÇ»ó µîÀ¸·Î Áø´Ü¿¡ »ç¿ëµÈ´Ù.
  • aggressive basal cell carcinoma
    ħ½À ±âÀú¼¼Æ÷¾Ï
  • air cell
    ÇԱ⠼¼Æ÷
  • alveolar cell carcinoma
    ÆóÆ÷ ¼¼Æ÷ ¾ÏÁ¾
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
V antigen Viral antigen that is intimately associated with the virus particle, is protein in nature, has multiple antigenicities, and is strain-specific; antibody to such antigen is demonstrable as protective or neutralizing antibody.
(05 Mar 2000)
variable antigen <immunology> Term usually applied to the surface antigens of those parasitic or pathogenic organisms that can alter their antigenic character to evade host immune responses. (See antigenic variation).
(18 Nov 1997)
G antigen An antigenic glycoprotein frequently associated with viral surfaces.
Origin: Ger. Gebundenes, bound
(05 Mar 2000)
major histocompatibility antigen <immunology> A set of plasmalemmal glycoprotein antigens involved in rapid (e.g. 7 days in the mouse) graft rejection and other immune phenomena. The minor histocompatibility antigens are involved in much slower rejection phenomena. The major antigens show remarkable polymorphism and occur as Class I and Class II types in mammals, birds may have a Class III molecule as well.
See: histocompatibility antigens, MHC restriction.
(18 Nov 1997)
P antigen <haematology, immunology> Antigenic determinant on the surface of human red blood cells to which the Donath Landsteiner antibody reacts.
This antibody binds in the cold (a cold IgG), but elutes from red cells at 37­C, is particularly associated with tertiary syphylis and its binding causes paroxysmal nocturnal haemoglobinuria.
(18 Nov 1997)
R antigen Those that produce active haemolysins (O and S) which cause a zone of clear haemolysis on the blood agar medium in the area of the colony; beta-haemolytic streptococci are divided into groups (A to O) on the basis of cell wall C carbohydrate (see Lancefield classification); Group A (in the strains pathogenic for man) comprises more than 50 types (designated by Arabic numerals) determined by cell wall M protein, which seems to be associated closely with virulence and is produced chiefly by strains with matt or mucoid colonies, in contrast to nonvirulent, glossy colony-producing strains; other surface protein antigens such as R and T (T substance), and the nucleoprotein fraction (P substance) seem to be of less importance. The more than 20 extracellular substances elaborated by strains of beta-haemolytic streptococci include erythrogenic toxin (elaborated only by lysogenic strains), deoxyribonuclease (streptodornase), haemolysins (streptolysins O and S), hyaluronidase, and streptokinase.
Synonym: haemolytic streptococci.
(05 Mar 2000)
M antigen An antigen found in the cell of Streptococcus pyogenes; associated with virulence.
See: beta-haemolytic streptococci.
(05 Mar 2000)
receptors, antigen Molecules on the surface of b- and T-lymphocytes that recognise and combine with specific antigens.
(12 Dec 1998)
receptors, very late antigen Members of the integrin family appearing late after T-cell activation. They are a family of proteins initially identified at the surface of stimulated T-cells, but now identified on a variety of cell types. At least six vla antigens have been identified as heterodimeric adhesion receptors consisting of a single common beta-subunit and different alpha-subunits.
(12 Dec 1998)
Gerbich antigen glycophorin C
Vi antigen Virulence antigen, an external capsular antigen of enterobacteria formerly thought to be related to increased virulence.
(05 Mar 2000)
partial antigen <immunology, molecular biology> Could be considered an isolated epitope: although a hapten (by definition) has an antibody directed against it, the hapten alone will not induce an immune response if injected into an animal, it must be conjugated to a carrier (usually a protein).
The hapten constitutes a single antigenic determinant, perhaps the best known example is dinitro phenol (DNP) that can be conjugated to BSA and against which antiDNP antibodies are produced (antibodies to the BSA can be adsorbed out).
Because the hapten is monovalent, immune complex formation will be blocked if the soluble hapten is present as well as the hapten carrier conjugate (assuming there is more than one hapten per carrier then an immune precipitate can be formed).
Competitive inhibition by the soluble small molecule is sometimes referred to as haptenic inhibition and this term has carried over into lectin mediated haemagglutination where monosaccharides are added to try to block haemagglutination: the blocking sugar defines the specificity of the lectin.
(18 Nov 1997)
viral antigen Those antigens specified by the viral genome (often coat proteins) that can be detected by a specific immunological response. Often of diagnostic importance.
(18 Nov 1997)
C carbohydrate antigen An antigen found in the cell wall of Streptococcus pneumoniae.
See: beta-haemolytic streptococci.
(05 Mar 2000)
CD antigen <immunology> Differentiation antigens residing on human leukocytes. CD stands for cluster of differentiation, which refers to groups of monoclonal antibodies that show similiar reactivity with certain subpopulations of antigens. The subpopulations of antigens are also known by the same CD designation.
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á